TKG Huchems acquires 10.8% stake in AprilBio for 150 billion won, diversifying business with put option agreement
TKG Huchems, along with joint investor IMM Asset Management, decided to acquire 3,492,189 convertible preferred shares of AprilBio for approximately 150 billion won. This represents 16.5% of TKG Huchems' equity of 908.3 billion won, resulting in a 10.8% stake and 11.2% voting rights after acquisition.
The purpose is to diversify business operations, aiming to secure growth momentum by entering the biotech sector. However, AprilBio recorded a net loss of 9.7 billion won in 2025, indicating unstable financial health and investment risk.
The contract includes a call option held by TKG Huchems, a put option and tag-along right for IMM, ensuring flexibility in future stake disposal. Additionally, a shareholders' agreement with CEO Cha Sang-hoon grants TKG Huchems a right of first refusal.
This acquisition is cash-based with no dilution effect, but the large cash outflow and high uncertainty in the biotech industry may weigh on short-term stock price. Long-term potential lies in portfolio diversification and stability enhancement.
[AI Summary]TKG Huchems' 150 billion won acquisition of AprilBio's stake diversifies into biotech, but the target's persistent losses and cash outflow pressure limit near-term earnings improvement. The contractual put option structure partially controls risk, and synergy with existing operations will be key to stock price direction.
KOSPI Filing Information
Decision on Acquisition of Stocks and Investment Securities of Other Corporations